4596.T
Kubota Pharmaceutical Holdings Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 64.00
−1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.0M | 21.0M | 27.0M | 40.0M | 8.0M |
| Cost of Revenue | 26.8M | 26.1M | 5.2M | 11.8M | 5.8M |
| Gross Profit | (7.8M) | (5.1M) | 21.8M | 28.2M | 2.2M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 541.3M | 543.0M | 710.5M | 632.8M | 601.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 541.3M | 543.0M | 710.5M | 632.8M | 601.3M |
| Cost and Expenses | 968.0M | 916.0M | 1.3B | 1.5B | 2.0B |
| Operating Income (EBIT) | (949.0M) | (895.0M) | (1.3B) | (1.5B) | (2.0B) |
| Non-Operating | |||||
| Interest Income | 2.5M | 1.9M | 5.7M | 13.9M | 18.5M |
| Interest Expense | 656.0K | 872.0K | 7.4M | 9.4M | 11.6M |
| Net Interest Income | 1.9M | 979.0K | (1.7M) | 4.5M | 6.9M |
| Other Non-Op Income/Expense | (435.0K) | (249.0K) | 14.3M | 9.9M | 15.2M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (729.8M) | (676.3M) | (1.3B) | (1.5B) | (2.0B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (729.0M) | (676.0M) | (1.3B) | (1.5B) | (2.0B) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (729.8M) | (676.3M) | (1.3B) | (1.5B) | (2.0B) |
| Per Share | |||||
| Basic EPS | (¥9) | (¥11) | (¥24) | (¥27) | (¥41) |
| Diluted EPS | (¥9) | (¥11) | (¥24) | (¥27) | (¥41) |
| Revenue Per Share | ¥0 | ¥0 | ¥0 | ¥1 | ¥0 |
| Shares | |||||
| Basic Shares Outstanding | 121.2M | 63.9M | 56.3M | 55.6M | 49.3M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | — | — |
| D&A | — | — | — | — | — |
| EBIT | (949.0M) | (895.0M) | (1.3B) | (1.5B) | (2.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026